Characterization of sporadic somatotropinomas with high GIP receptor expression.
GIPR
GNAS
Oral glucose tolerance test (OGTT)
Somatostatin receptor ligands
Sporadic somatotropinomas
gsp
Journal
Pituitary
ISSN: 1573-7403
Titre abrégé: Pituitary
Pays: United States
ID NLM: 9814578
Informations de publication
Date de publication:
Dec 2022
Dec 2022
Historique:
accepted:
08
08
2022
pubmed:
7
9
2022
medline:
23
11
2022
entrez:
6
9
2022
Statut:
ppublish
Résumé
To analyze the expression of glucose-dependent insulinotropic polypeptide receptor (GIPR) in somatotropinomas specimens and compare clinical, biochemical, radiological, therapeutic, molecular, and pathological data among those who overexpressed (GIPR +) and those who did not overexpress (GIPR - ) GIPR. Clinical, biochemical, radiological, molecular, and pathological data were collected. GNAS1 sequencing was performed with the Sanger method. Protein expression of somatostatin receptor subtypes 2 and 5 and CAM 5.2 were analyzed by immunohistochemistry. Quantitative real-time PCR was performed to analyze the mRNA expression of GIPR with the TaqMan® method. Positive expression was considered when the fold change (FC) was above 17.2 (GIPR +). A total of 74 patients (54% female) were included. Eighteen tumors (24%) were GIPR + . Gsp mutation was detected in 30 tumors (40%). GIPR + tumors were more frequently densely granulated adenomas (83% vs 47%, p = 0.028). There was no difference in clinical, biochemical, radiological, therapeutic (surgical cure or response to medical therapy), or other pathological features between GIPR + and GIPR - tumors. Twenty-eight out of 56 (50%) GIPR - tumors harbored a gsp mutation, whereas two out of 18 (11%) GIPR + tumors harbored a gsp mutation (p = 0.005). We described, for the first time, that GIPR + and gsp mutations are not mutually exclusive, but gsp mutations are less common in GIPR + tumors. GIPR + and GIPR - tumors have similar clinical, biochemical, radiological, therapeutic, and pathological features, with the exception of a high frequency of densely granulated adenomas among GIPR + tumors.
Identifiants
pubmed: 36066838
doi: 10.1007/s11102-022-01272-6
pii: 10.1007/s11102-022-01272-6
doi:
Substances chimiques
gastric inhibitory polypeptide receptor
D6H00MV7K8
Receptors, Gastrointestinal Hormone
0
Antibodies, Monoclonal
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
903-910Informations de copyright
© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Références
Gadelha MR, Kasuki L, Korbonits M (2017) The genetic background of acromegaly. Pituitary 20(1):10–21. https://doi.org/10.1007/s11102-017-0789-7
doi: 10.1007/s11102-017-0789-7
pubmed: 28161730
pmcid: 5334425
Katznelson L, Laws ER Jr, Melmed S, Molitch ME, Murad MH, Utz A et al (2014) Acromegaly: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 99(11):3933–3951. https://doi.org/10.1210/jc.2014-2700
doi: 10.1210/jc.2014-2700
pubmed: 25356808
Melmed S, Casanueva FF, Klibanski A, Bronstein MD, Chanson P, Lamberts SW et al (2013) A consensus on the diagnosis and treatment of acromegaly complications. Pituitary 16(3):294–302. https://doi.org/10.1007/s11102-012-0420-x
doi: 10.1007/s11102-012-0420-x
pubmed: 22903574
Gadelha MR, Kasuki L, Lim DST, Fleseriu M (2019) Systemic complications of acromegaly and the impact of the current treatment landscape: an update. Endocr Rev 40(1):268–332. https://doi.org/10.1210/er.2018-00115
doi: 10.1210/er.2018-00115
pubmed: 30184064
Bi WL, Horowitz P, Greenwald NF, Abedalthagafi M, Agarwalla PK, Gibson WJ et al (2017) Landscape of genomic alterations in pituitary adenomas. Clin Cancer Res 23(7):1841–1851. https://doi.org/10.1158/1078-0432.Ccr-16-0790
doi: 10.1158/1078-0432.Ccr-16-0790
pubmed: 27707790
Ronchi CL, Peverelli E, Herterich S, Weigand I, Mantovani G, Schwarzmayr T et al (2016) Landscape of somatic mutations in sporadic GH-secreting pituitary adenomas. Eur J Endocrinol 174(3):363–372. https://doi.org/10.1530/eje-15-1064
doi: 10.1530/eje-15-1064
pubmed: 26701869
Song ZJ, Reitman ZJ, Ma ZY, Chen JH, Zhang QL, Shou XF et al (2016) The genome-wide mutational landscape of pituitary adenomas. Cell Res 26(11):1255–1259. https://doi.org/10.1038/cr.2016.114
doi: 10.1038/cr.2016.114
pubmed: 27670697
pmcid: 5099864
Välimäki N, Demir H, Pitkänen E, Kaasinen E, Karppinen A, Kivipelto L et al (2015) Whole-genome sequencing of growth hormone (GH)-secreting pituitary adenomas. J Clin Endocrinol Metab 100(10):3918–3927. https://doi.org/10.1210/jc.2015-3129
doi: 10.1210/jc.2015-3129
pubmed: 26280510
Fougner SL, Borota OC, Berg JP, Hald JK, Ramm-Pettersen J, Bollerslev J (2008) The clinical response to somatostatin analogues in acromegaly correlates to the somatostatin receptor subtype 2a protein expression of the adenoma. Clin Endocrinol (Oxf) 68(3):458–465. https://doi.org/10.1111/j.1365-2265.2007.03065.x
doi: 10.1111/j.1365-2265.2007.03065.x
Taboada GF, Neto LV, Luque RM, Córdoba-Chacón J, de Oliveira ME, de Carvalho DP et al (2011) Impact of gsp oncogene on the mRNA content for somatostatin and dopamine receptors in human somatotropinomas. Neuroendocrinology 93(1):40–47. https://doi.org/10.1159/000322040
doi: 10.1159/000322040
pubmed: 21079388
Efstathiadou ZA, Bargiota A, Chrisoulidou A, Kanakis G, Papanastasiou L, Theodoropoulou A et al (2015) Impact of gsp mutations in somatotroph pituitary adenomas on growth hormone response to somatostatin analogs: a meta-analysis. Pituitary 18(6):861–867. https://doi.org/10.1007/s11102-015-0662-5
doi: 10.1007/s11102-015-0662-5
pubmed: 26115707
Occhi G, Losa M, Albiger N, Trivellin G, Regazzo D, Scanarini M et al (2011) The glucose-dependent insulinotropic polypeptide receptor is overexpressed amongst GNAS1 mutation-negative somatotropinomas and drives growth hormone (GH)-promoter activity in GH3 cells. J Neuroendocrinol 23(7):641–649. https://doi.org/10.1111/j.1365-2826.2011.02155.x
doi: 10.1111/j.1365-2826.2011.02155.x
pubmed: 21554434
Harris PE, Alexander JM, Bikkal HA, Hsu DW, Hedley-Whyte ET, Klibanski A et al (1992) Glycoprotein hormone alpha-subunit production in somatotroph adenomas with and without Gs alpha mutations. J Clin Endocrinol Metab 75(3):918–923. https://doi.org/10.1210/jcem.75.3.1517386
doi: 10.1210/jcem.75.3.1517386
pubmed: 1517386
Spada A, Arosio M, Bochicchio D, Bazzoni N, Vallar L, Bassetti M et al (1990) Clinical, biochemical, and morphological correlates in patients bearing growth hormone-secreting pituitary tumors with or without constitutively active adenylyl cyclase. J Clin Endocrinol Metab 71(6):1421–1426. https://doi.org/10.1210/jcem-71-6-1421
doi: 10.1210/jcem-71-6-1421
pubmed: 1977758
Yang IM, Woo JT, Kim SW, Kim JW, Kim YS, Choi YK (1995) Characteristics of acromegalic patients with a good response to octreotide, a somatostatin analogue. Clin Endocrinol (Oxf) 42(3):295–301. https://doi.org/10.1111/j.1365-2265.1995.tb01878.x
doi: 10.1111/j.1365-2265.1995.tb01878.x
Fougner SL, Casar-Borota O, Heck A, Berg JP, Bollerslev J (2012) Adenoma granulation pattern correlates with clinical variables and effect of somatostatin analogue treatment in a large series of patients with acromegaly. Clin Endocrinol (Oxf) 76(1):96–102. https://doi.org/10.1111/j.1365-2265.2011.04163.x
doi: 10.1111/j.1365-2265.2011.04163.x
Freda PU, Chung WK, Matsuoka N, Walsh JE, Kanibir MN, Kleinman G et al (2007) Analysis of GNAS mutations in 60 growth hormone secreting pituitary tumors: correlation with clinical and pathological characteristics and surgical outcome based on highly sensitive GH and IGF-I criteria for remission. Pituitary 10(3):275–282. https://doi.org/10.1007/s11102-007-0058-2
doi: 10.1007/s11102-007-0058-2
pubmed: 17594522
Baggio LL, Drucker DJ (2007) Biology of incretins: GLP-1 and GIP. Gastroenterology 132(6):2131–2157. https://doi.org/10.1053/j.gastro.2007.03.054
doi: 10.1053/j.gastro.2007.03.054
pubmed: 17498508
Fehmann HC, Göke R, Göke B (1995) Cell and molecular biology of the incretin hormones glucagon-like peptide-I and glucose-dependent insulin releasing polypeptide. Endocr Rev 16(3):390–410. https://doi.org/10.1210/edrv-16-3-390
doi: 10.1210/edrv-16-3-390
pubmed: 7671853
Calanna S, Christensen M, Holst JJ, Laferrère B, Gluud LL, Vilsbøll T et al (2013) Secretion of glucose-dependent insulinotropic polypeptide in patients with type 2 diabetes: systematic review and meta-analysis of clinical studies. Diabetes Care 36(10):3346–3352. https://doi.org/10.2337/dc13-0465
doi: 10.2337/dc13-0465
pubmed: 24065842
pmcid: 3781498
Regazzo D, Barbot M, Scaroni C, Albiger N, Occhi G (2020) The pathogenic role of the GIP/GIPR axis in human endocrine tumors: emerging clinical mechanisms beyond diabetes. Rev Endocr Metab Disord 21(1):165–183. https://doi.org/10.1007/s11154-019-09536-6
doi: 10.1007/s11154-019-09536-6
pubmed: 31933128
Regazzo D, Losa M, Albiger NM, Terreni MR, Vazza G, Ceccato F et al (2017) The GIP/GIPR axis is functionally linked to GH-secretion increase in a significant proportion of gsp(-) somatotropinomas. Eur J Endocrinol 176(5):543–553. https://doi.org/10.1530/eje-16-0831
doi: 10.1530/eje-16-0831
pubmed: 28179449
Peracchi M, Porretti S, Gebbia C, Pagliari C, Bucciarelli P, Epaminonda P et al (2001) Increased glucose-dependent insulinotropic polypeptide (GIP) secretion in acromegaly. Eur J Endocrinol 145(1):R1-4. https://doi.org/10.1530/eje.0.145r001
doi: 10.1530/eje.0.145r001
pubmed: 11415859
Scaroni C, Albiger N, Daniele A, Dassie F, Romualdi C, Vazza G et al (2019) Paradoxical GH increase during OGTT is associated with first-generation somatostatin analog responsiveness in acromegaly. J Clin Endocrinol Metab 104(3):856–862. https://doi.org/10.1210/jc.2018-01360
doi: 10.1210/jc.2018-01360
pubmed: 30285115
Beck P, Parker ML, Daughaday WH (1966) Paradoxical hypersecretion of growth hormone in response to glucose. J Clin Endocrinol Metab 26(4):463–469. https://doi.org/10.1210/jcem-26-4-463
doi: 10.1210/jcem-26-4-463
pubmed: 5929631
Hage M, Janot C, Salenave S, Chanson P, Kamenický P (2021) Management of endocrine disease: etiology and outcome of acromegaly in patients with a paradoxical GH response to glucose. Eur J Endocrinol 184(6):R261–R268. https://doi.org/10.1530/eje-20-1448
doi: 10.1530/eje-20-1448
pubmed: 33830942
Atquet V, Alexopoulou O, Maiter D (2021) Characteristics and treatment responsiveness of patients with acromegaly and a paradoxical GH increase to oral glucose load. Eur J Endocrinol. https://doi.org/10.1530/eje-21-0324
doi: 10.1530/eje-21-0324
pubmed: 34085950
Umahara M, Okada S, Ohshima K, Mori M (2003) Glucose-dependent insulinotropic polypeptide induced growth hormone secretion in acromegaly. Endocr J 50(5):643–650. https://doi.org/10.1507/endocrj.50.643
doi: 10.1507/endocrj.50.643
pubmed: 14614222
Hage M, Chaligné R, Viengchareun S, Villa C, Salenave S, Bouligand J et al (2019) Hypermethylator phenotype and ectopic GIP receptor in GNAS mutation-negative somatotropinomas. J Clin Endocrinol Metab 104(5):1777–1787. https://doi.org/10.1210/jc.2018-01504
doi: 10.1210/jc.2018-01504
pubmed: 30376114
Micko AS, Wöhrer A, Wolfsberger S, Knosp E (2015) Invasion of the cavernous sinus space in pituitary adenomas: endoscopic verification and its correlation with an MRI-based classification. J Neurosurg 122(4):803–811. https://doi.org/10.3171/2014.12.Jns141083
doi: 10.3171/2014.12.Jns141083
pubmed: 25658782
Giustina A, Barkhoudarian G, Beckers A, Ben-Shlomo A, Biermasz N, Biller B et al (2020) Multidisciplinary management of acromegaly: a consensus. Rev Endocr Metab Disord 21(4):667–678. https://doi.org/10.1007/s11154-020-09588-z
doi: 10.1007/s11154-020-09588-z
pubmed: 32914330
pmcid: 7942783
Normann KR, Øystese KAB, Berg JP, Lekva T, Berg-Johnsen J, Bollerslev J et al (2016) Selection and validation of reliable reference genes for RT-qPCR analysis in a large cohort of pituitary adenomas. Mol Cell Endocrinol 437:183–189. https://doi.org/10.1016/j.mce.2016.08.030
doi: 10.1016/j.mce.2016.08.030
pubmed: 27561203
Gatto F, Feelders RA, van der Pas R, Kros JM, Waaijers M, Sprij-Mooij D et al (2013) Immunoreactivity score using an anti-sst2A receptor monoclonal antibody strongly predicts the biochemical response to adjuvant treatment with somatostatin analogs in acromegaly. J Clin Endocrinol Metab 98(1):E66-71. https://doi.org/10.1210/jc.2012-2609
doi: 10.1210/jc.2012-2609
pubmed: 23118420
Obari A, Sano T, Ohyama K, Kudo E, Qian ZR, Yoneda A et al (2008) Clinicopathological features of growth hormone-producing pituitary adenomas: difference among various types defined by cytokeratin distribution pattern including a transitional form. Endocr Pathol 19(2):82–91. https://doi.org/10.1007/s12022-008-9029-z
doi: 10.1007/s12022-008-9029-z
pubmed: 18629656
Lopes MBS (2017) The 2017 World Health Organization classification of tumors of the pituitary gland: a summary. Acta Neuropathol 134(4):521–535. https://doi.org/10.1007/s00401-017-1769-8
doi: 10.1007/s00401-017-1769-8
pubmed: 28821944
Peñalva A, Burguera B, Casabiell X, Tresguerres JA, Dieguez C, Casanueva FF (1989) Activation of cholinergic neurotransmission by pyridostigmine reverses the inhibitory effect of hyperglycemia on growth hormone (GH) releasing hormone-induced GH secretion in man: does acute hyperglycemia act through hypothalamic release of somatostatin? Clin Trial 49:551
Mancini A, Bianchi A, Gentilella R, Valle D, Giampietro A et al (2002) Preoperative growth hormone response to thyrotropin-releasing hormone and oral glucose tolerance test in acromegaly: a retrospective evaluation of 50 patients. Metabolism. 51(5):616–621. https://doi.org/10.1053/meta.2002.32017
doi: 10.1053/meta.2002.32017
pubmed: 11979395
Valcavi R (1996) Oral glucose tolerance test: an inhibitory or a stimulatory input to growth hormone secretion? J Endocrinol Invest 19(4):253–255. https://doi.org/10.1007/BF03349877
doi: 10.1007/BF03349877
pubmed: 8862507
Barlier A, Gunz G, Zamora AJ, Morange-Ramos I, Figarella-Branger D, Dufour H et al (1998) Pronostic and therapeutic consequences of Gs alpha mutations in somatotroph adenomas. J Clin Endocrinol Metab 83(5):1604–1610. https://doi.org/10.1210/jcem.83.5.4797
doi: 10.1210/jcem.83.5.4797
pubmed: 9589663
Faglia G, Arosio M, Spada A (1996) GS protein mutations and pituitary tumors: functional correlates and possible therapeutic implications. Metabolism 45(8 Suppl 1):117–119. https://doi.org/10.1016/s0026-0495(96)90103-1
doi: 10.1016/s0026-0495(96)90103-1
pubmed: 8769403